- Home
- BIRD vs TPST Comparison
BIRD vs TPST Comparison
Compare BIRD & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | TPST |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 30.9M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BIRD | TPST |
|---|---|---|
| Price | $7.24 | $1.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 13.8M | 303.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $1.50 |
| 52 Week High | $24.31 | $12.22 |
Technical Indicators
Market Signals| Indicator | BIRD | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 44.40 |
| Support Level | $4.24 | $1.50 |
| Resistance Level | $9.87 | $2.48 |
| Average True Range (ATR) | 2.46 | 0.22 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 21.83 | 30.00 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.